There's no doubt about it: preventative cancer screening can save lives. But new evidence suggests that some screenings may be inappropriate and even risky.

False-positives are a potential downside of breast cancer screening, and one that the US Preventive Services Task Force (USPSTF) says patients and their doctors should consider.

The US Preventive Services Task Force (USPSTF) has now issued its final recommendations on breast cancer screening, including a discussion of the potential benefits and harms of mammography performed every two years.

Doctors may now have a new — and equally effective — breast cancer screening tool in their arsenal.

Young women with invasive breast cancer are often faced with a difficult choice: whether or not to undergo chemotherapy despite its risk of infertility.

The current front-line treatment for early breast cancer, tamoxifen, may have met its match.

Chemotherapy can greatly improve cancer patients' chances of survival. But with this treatment comes a serious and equally life-threatening risk: heart failure.

Breast cancer patients and their doctors may now have a new tool in their toolbox.

Nearly all postmenopausal women with early-stage HR+ breast cancer are treated with aromatase inhibitors. But these drugs can significantly compromise bone health and up the risk of fractures.